Mouse Anti-Human C5aR1 Monoclonal Antibody (TJL-183) [Allophycocyanin](Cat#: CTMM-0322-JL1878)
This product is a Allophycocyanin conjugated anti-Human Complement C5aR1 Monoclonal antibody (TJL-183) generated from the Mouse. The antibody can be used for Flow.
Summary
Related Products & Services
Specifications
| Clonality |
Monoclonal |
| Clone |
TJL-183 |
| Host Animal |
Mouse |
| Isotype |
IgG2a |
| Immunogen |
Recombinant Human C1QBP/GC1qR purified from E.coli., a.a. 74-282 |
| Species Reactivity |
Human |
| Applications |
Flow |
| Application Notes |
Flow: 0.25-1 ug/106 cells |
| Specificity |
This antibody reacts with Human Complement C5aR1. |
| Purity |
≥95% as determined by SDS-PAGE |
| Conjugation |
Allophycocyanin |
| Format |
Liquid |
| Size |
0.1 ml |
| Storage |
Store in dark at 4°C. Do Not Freeze. |
| Type |
Primary Antibody |
Target
| Target Name |
C5aR1 |
| Alternative Names |
Complement C5a Receptor 1; Complement Component 5a Receptor 1; C5a-R; C5R1; C5AR; Complement Component 5 Receptor 1 (C5a Ligand); C5a Anaphylatoxin Chemotactic Receptor 1; C5a Anaphylatoxin Chemotactic Receptor; Complement Component 5 Receptor 1; C5a Anaphylatoxin Receptor; CD88 Antigen; C5a Ligand; CD88; C5aR; C5A |
| Gene ID |
728 |
| UniProt ID |
P21730 |
Information
| Introduction |
The C5a receptor also known as complement component 5a receptor 1 (C5AR1) or CD88 (Cluster of Differentiation 88) is a G protein-coupled receptor for C5a. It functions as a complement receptor. C5a receptor modulates inflammatory responses, obesity, development and cancers. eceptor for the chemotactic and inflammatory peptide anaphylatoxin C5a). The ligand interacts with at least two sites on the receptor: a high-affinity site on the extracellular N-terminus, and a second site in the transmembrane region which activates downstream signaling events. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production |
For Research Use Only. Not for Diagnostic or Therapeutic Applications.
